In this study, the authors indicate that despite two subtypes of immune and inflamed SCLC tumours have been defined, for which both are expected to be responsive to immunotherapy, NE tumours characterised by a low level of infiltrating macrophages are responsive to anti-PD-L1 treatment plus chemotherapy, unlike non-NE tumours with high levels of macrophages [28]. The gene discussed is CD274; the disease is small cell lung carcinoma.